Natriumcromoglicaat Teva (Sodium Cromoglicate)

Sodium Cromoglicate, the active ingredient in Natriumcromoglicaat Teva, is a mast cell stabilizer presented as a nasal spray for endosinusial, intracavernous and nasal use. It is employed to manage allergic inflammation of the nasal passages and sinuses in patients with allergic rhinitis or sinusitis.

GNH USA supplies Natriumcromoglicaat Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sodium Cromoglicate acts on mast‑cell mediated allergic pathways to reduce nasal and sinus inflammation. - Allergic rhinitis: alleviates nasal congestion, itching and sneezing caused by seasonal or perennial allergens. - Allergic sinusitis: helps decrease sinus pressure, discharge and facial pain associated with allergic sinus inflammation. - Mast‑cell mediated nasal irritation: reduces histamine release and improves nasal airflow.

Adverse reactions may occur with any mast cell stabilizer and are reported in clinical use.

Common Side Effects: - Nasal irritation or burning sensation - Throat irritation or mild cough - Headache - Unpleasant taste or taste disturbance - Mild epistaxis (nosebleed) - Sneezing

Serious or Rare Side Effects: - Anaphylactic reaction - Severe bronchospasm - Angioedema of the face or throat - Significant nasal bleeding - Persistent wheezing or difficulty breathing - Severe allergic dermatitis

When using Sodium Cromoglicate, consider the following safety measures. - Contraindications: Do not use in patients with known hypersensitivity to cromoglicate or any formulation components. - Pregnancy: Use only if the potential benefit justifies the potential risk; consult a healthcare professional. - Breastfeeding: Caution advised; discuss with a physician before use. - Monitoring: Observe for signs of worsening respiratory symptoms or unexpected allergic reactions. - Storage: Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Sodium Cromoglicate may interact with other medications that affect mast cell stability or respiratory function.

Major Interactions (Avoid): - Beta‑agonists (e.g., albuterol): may reduce bronchodilator efficacy when used concurrently. - Other mast‑cell stabilizers: combined use can increase risk of local irritation.

Moderate Interactions (Monitor Closely): - Antihistamines: additive sedative effects are unlikely but monitor patient comfort. - Corticosteroid nasal sprays: may increase local irritation; assess tolerability. - MAO inhibitors: no direct interaction, but monitor for any unexpected nasal symptoms.